3sbio-银河电玩城

dr. lou jing, was appointed as a director on 5 september 2006 and was redesignated as an executive director on 27 november 2014. he was appointed as the chairman of the board on 1 april 2012. dr. lou is also the chief executive officer of the company. he is responsible for the strategic development and planning, overall operational management and major decision making of the group. he is a co-founder of the group and joined shenyang sunshine pharmaceutical company limited (“shenyang sunshine”) as a director of r&d in september 1995.

dr. lou also holds the following positions with other members of the group:
1) director and chairman of the board of collected mind limited (集思有限公司, “collected mind”);
2) director of hongkong sansheng;
3) director of excel partner holdings limited (特隆控股有限公司, “excel partner”);
4) director of ample harvest investments limited (溢丰投资有限公司, “ample harvest”);
5) director, chief executive officer and president of shenyang sunshine and chairman of the board of shenyang sunshine;
6) director and general manager of liaoning sunshine bio-pharmaceutical company limited (辽宁三生医药有限公司, “liaoning sunshine”);
7) director and chairman of the board of taizhou huan sheng investment management company limited (泰州环晟投资管理有限公司, “taizhou huan sheng investment”);
8) executive director of shenzhen baishitong technology development company limited (深圳市百士通科技开发有限公司, “shenzhen baishitong”);
9) chairman of the board of shenzhen sciprogen bio-pharmaceutical co., ltd. (“sciprogen”);
10) chairman of the board of guangdong sciprogen bio-pharmaceutical technology co., ltd. (广东赛保尔生物医药技术有限公司, “guangdong sciprogen”);
11) chairman of the board of guangdong sunshine pharmaceutical co., ltd. (广东三生制药有限公司);
12) director of gains prestige limited (泽威有限公司, “gains prestige”);
13) director of strategic international group limited (“strategic international”);
14) director and chairman of the board of sunshine guojian pharmaceutical (shanghai) co., ltd. (“sunshine guojian”);
15) director and chairman of the board of shanghai xingsheng pharmaceutical company limited (“xing sheng”);
16) director of thunderpure international limited;
17) director of thunderpharma international limited;
18) director of wellesley hill capital limited; and
19) director of thunderpharma international (hk) limited.

dr. lou has been highly active in pharmaceutical research and has made substantial contribution to the group’s r&d of pharmaceutical products. dr. lou was the leading scientist and principal investigator in the group’s successful development of epiao and tpiao. he co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. he has published in a number of academic journals on microbiology and medicinal biotechnology. his research has been recognized with various awards. in 2006, he was awarded the “first prize of shenyang science and technology progress award” (沈阳市科学技术进步一等奖) for his research on recombinant human thrombopoietin. in 2007, he was awarded the “third prize of liaoning province scientific and technological achievements” (辽宁省科学成果转化三等奖) for his contribution to the industrialization of production of recombinant human thrombopoietin. in 2017, he was awarded “liaoning province outstanding entrepreneur” and “friendship award of liaoning province”. dr. lou obtained a medical doctor degree (m.d.) in clinical medicine from shanghai second military medical university in july 1985. he conducted post-doctoral research at the national institutes of health of the united states after obtaining a ph.d. degree in molecular and cell biology from fordham university in the united states in february 1994. he also obtained an executive master of business administration from china europe international business school (中欧国际工商学院) in september 2008.

ms. su dongmei was appointed as the director of the company on june 11, 2012 and was transferred to be an executive director of the company on november 27, 2014. ms. su is also our senior vice president. she is responsible for the group’s strategic direction and leading the r&d. ms. su joined shenyang sunshine in january 1993 as a scientist of r&d department and served as the head of r&d department from 1997 to 2006. she was then the chief technical officer of shenyang sunshine from 2006 to 2008, responsible for r&d and manufacturing process engineering. ms. su was promoted to vice president of shenyang sunshine in april 2008. ms. su was a director of shenyang sunshine from august 2007 to june 2013. ms. su is the co-inventor of our four patents.

ms. su obtained a bachelor degree in biochemistry from jilin university in july 1992 and a master degree and a doctorate degree in microbiology and pharmacology from shenyang pharmaceutical university in june 2001 and july 2010 respectively. she has published materials on microbiology and pharmaceutical biopharmaceuticals in several academic publications.

mr. huang bin was firstly appointed as the director of the company in september 2006, and ceased to serve as a director in may 2013. mr. huang was re-appointed as an executive director of the company in november 2014.  before the redesignation from his position as an executive director to a non-executive director in june 2019, he was also our vice president, responsible for the management of the group and the operation management of subsidiaries and joint ventures. mr. huang joined shenyang sunshine in 1993 as manager of human resources department. mr. huang obtained a diploma in engineering from northeastern institute of technology (now northeastern university) in july 1987. from april 2000 to april 2001, he attended a one-year training course in business administration at tsinghua university.

mr. tang, aged 40, has more than 15 years of work experience in the investment sector. mr. tang joined citic private equity funds management co., ltd (“citic pe”) in 2013 and had held various positions, including vice president, director and principal director, before he became in charge of the investment department of the healthcare sector at citic pe. mr. tang has substantial experience in corporate investment, strategic planning, capital operation and corporate management. mr. tang served as an associate and executive director at the investment banking division of goldman sachs gao hua from 2008 to 2011 and later served as an investment manager at the principal investment department of goldman sachs group from 2012 to 2013. he was also a director in beigene, ltd. (a listed company on nasdaq at the time when he was a director which has been dually listed on nasdaq and the stock exchange since 2018) from 2014 to 2017 and biosensors international group, ltd. (a company formerly listed on singapore exchange securities trading limited which was subsequently delisted in 2016) from 2016 to 2018. mr. tang also serves as a director of bluesail medical co., ltd.* ( 藍帆醫療股份有限公 司 ) (a company listed on the shenzhen stock exchange: 002382) and shanghai hanyu medical technology co., ltd.* ( 上海捍宇醫療科技有限公司 ), and as the chairman of the board of directors of spectrum dynamics medical group limited, jw icu medical ltd.* ( 威海吉威重症 醫療製品有限公司), a subsidiary of biosensors international pte ltd., beijing everlife healthcare hospital management company limited* ( 北京長生眾康醫院管理有限公司 ) and acotec scientific co. ltd* ( 北京先瑞達醫療科技有限公司 ), respectively. mr. tang obtained his bachelor of arts from southeast university and his master of business administration from the kellogg school of management of the northwestern university.

mr. pu tianruo, was appointed as an independent non-executive director on 23 may 2015, with such appointment taking effect on 1 june 2015. he is responsible for participating in decision-making and advising on issues relating to the company’s significant events and corporate governance. previously, he served as an independent director and the audit committee chair of the company from 1 september 2012 to 29 may 2013.

mr. pu has substantial experience in accounting and finance. he has served as an independent non-executive director of several companies, including jmu limited (a company listed on the nasdaq with symbol jmu) since april 2015, autohome inc. (a company listed on the nyse with symbol athm) since december 2016, and renren inc. (a company listed on the nyse with symbol renn) since december 2016. mr. pu was previously the chief financial officer of zhaopin ltd. (a company listed on the nyse with symbol zpin). mr. pu obtained a bachelor’s degree in english from china foreign affairs university (外交学院) in july 1991, a master’s degree in accounting from the university of illinois, college of business administration in may 1996 and a master of business administration degree from northwestern university kellogg school of management in june 2000.

dr. david ross parkinson was appointed as an independent non-executive director on may 23, 2015 and the appointment took effect on june 1, 2015. he is responsible for participating in decision-making and consulting on major issues and corporate governance issues of the company.

from 2007 to 2012, dr. parkinson served as president and ceo of nodality, inc. (a biotechnology company focusing on personalized medicine). by this, he was the vice president and director of clinical oncology treatment at amgen inc. (a company listed on the nasdaq stock market, stock code: amgn).

dr. parkinson served as a director of the american association for cancer research (aacr) from 2006 to 2009. he previously served in the national cancer policy forum of the institute of medicine from 2005 to 2011.

dr. parkinson received a number of awards and great honors, including the best innovation award by multiple myeloma research fund in 2012 and wiley medal by usfda in 1997. in 2008, he published the 12th andrew h. weinberg commemorative speech at harvard medical school.

dr. parkinson received a doctorate degree in medical science from the university of toronto in 1974.

dr. wong lap yan, aged 49, is a chartered biologist and fellow of the royal society of biology and a chartered scientist of the science council of the united kingdom. dr. wong has over 20 years of work experience with various highly respectable healthcare and biopharmaceutical companies, genetic services providers and academia in biology, including conducting antibody cancer research in translational oncology at genentech inc. (formerly listed on nyse: dna and now a subsidiary of roche), research in pharmacokinetics and drug metabolism at amgen inc. (listed on nasdaq: amgn) and pharmaceutical research at sri international (a scientific research institute established by the trustees of stanford university) in the united states. his research work has contributed to the discovery, research and development of cancer target therapy drugs, including bevacizumab (avastin) and vemurafenib (zelboraf), which are medication used to treat different types of cancers and specific eye diseases. he has published numerous medical research articles and abstracts in journals on different topics, including cancer and nutritional science, which have been cited extensively by peer scientists and researchers. dr. wong has also served as a postdoctoral fellow at the faculty of medicine at the university of hong kong and as a chief executive officer of a biotechnology company in hong kong. dr. wong is now the chief scientific officer and principal scientist of alom intelligence limited that offers deep learning technology and analytical solutions relating to healthcare and financial data, and a director and founder of cannan biotech limited that offers personal genetic technology consultancy services. dr. wong obtained his bachelor of science in human biology from the university of toronto, canada and doctor of philosophy in biological sciences from the university of hong kong.